$90 Billion. Gone.
That’s not theoretical. And patients pay the price.
When my co-founder Stephen Hom and I were frontline pharmacists, we saw what leakage looked like:
- Patients walking away from the counter
- Delayed therapy over the lack of a $50 copay card
Later, working with pharma execs, we saw the other side:
- Billions in support programs being misappropriated
- Dollars vanishing to accumulators, maximizers, and inefficiencies
That’s why we built RIS Rx, to stop the leakage in real time. Because the dollars matter. But the patients behind them matter even more.
In 2024, we helped recover $450M.
In 2025, we’re on track for $1B+.
And we’re just getting started.
I share more about how we help with Gross-to-Net leakage in a new piece published on Drug Channels here: asmbly.link/txJOlSF
The $90 billion in pharma leakage isn’t theoretical—it’s measurable, solvable, and costing manufacturers every day.
